Literature DB >> 22366814

ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).

David Adler1, Nicolas Wernert.   

Abstract

The ETS family of transcription factors is known to play important roles in various biological processes such as development, differentiation, proliferation, apoptosis, migration, tissue remodeling, invasion and angiogenesis in various cell types including B cells, endothelial cells, fibroblasts as well as diverse neoplastic cells. In prostate cancer, recurrent gene fusions involving members of the ETS family are frequently reported. ETS-1, the prototype of the ETS family, is expressed in different cell types and is known to play various roles during both physiological and pathological conditions. In this review, we focus on studies investigating the role of ETS-1 in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366814     DOI: 10.3892/ijo.2012.1380

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  30 in total

1.  c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

Authors:  Stefano Sioletic; Jeffrey Czaplinski; Lan Hu; Jonathan A Fletcher; Christopher D M Fletcher; Andrew J Wagner; Massimo Loda; George D Demetri; Ewa T Sicinska; Eric L Snyder
Journal:  J Pathol       Date:  2014-08-01       Impact factor: 7.996

2.  HIPK2 is necessary for type I interferon-mediated antiviral immunity.

Authors:  Lili Cao; Guang Yang; Shandian Gao; Chunxia Jing; Ruth R Montgomery; Yuxin Yin; Penghua Wang; Erol Fikrig; Fuping You
Journal:  Sci Signal       Date:  2019-03-19       Impact factor: 8.192

3.  Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.

Authors:  Zejia Yang; Jipei Liao; Kevin J Cullen; Hancai Dan
Journal:  Cell Death Discov       Date:  2020-05-15

Review 4.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

5.  Genome-wide prediction of cancer driver genes based on SNP and cancer SNV data.

Authors:  Quanze He; Quanyuan He; Xiaohui Liu; Youheng Wei; Suqin Shen; Xiaohui Hu; Qiao Li; Xiangwen Peng; Lin Wang; Long Yu
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

6.  MicroRNA-221/222 regulate ox-LDL-induced endothelial apoptosis via Ets-1/p21 inhibition.

Authors:  Bing Qin; Yuze Cao; Huan Yang; Bo Xiao; Zhengqi Lu
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

7.  The context of prostate cancer genomics in personalized medicine.

Authors:  Yanling Liu
Journal:  Oncol Lett       Date:  2017-03-24       Impact factor: 2.967

8.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

9.  ETS-1-mediated transcriptional up-regulation of CD44 is required for sphingosine-1-phosphate receptor subtype 3-stimulated chemotaxis.

Authors:  Wenliang Zhang; Jiawei Zhao; Jen-Fu Lee; Allison Gartung; Hiba Jawadi; Wanyu Louis Lambiv; Kenneth V Honn; Menq-Jer Lee
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

10.  Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.

Authors:  Haydn Thomas Kissick; Martin George Sanda; Laura Kathleen Dunn; Mohamed Simo Arredouani
Journal:  Cancer Immunol Immunother       Date:  2013-10-23       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.